WO2019209058A1 - Préparation pharmaceutique - Google Patents

Préparation pharmaceutique Download PDF

Info

Publication number
WO2019209058A1
WO2019209058A1 PCT/KR2019/005029 KR2019005029W WO2019209058A1 WO 2019209058 A1 WO2019209058 A1 WO 2019209058A1 KR 2019005029 W KR2019005029 W KR 2019005029W WO 2019209058 A1 WO2019209058 A1 WO 2019209058A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
mixing portion
pharmaceutical combination
amlodipine
rosuvastatin
Prior art date
Application number
PCT/KR2019/005029
Other languages
English (en)
Korean (ko)
Inventor
박준홍
김민정
차진선
박유빈
김예린
Original Assignee
제일약품주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제일약품주식회사 filed Critical 제일약품주식회사
Publication of WO2019209058A1 publication Critical patent/WO2019209058A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a pharmaceutical combination comprising telmisartan, rosuvastatin and amlodipine as active ingredients. More specifically, the present invention includes a first mixing portion containing telmisartan as an active ingredient and a second mixing portion containing rosuvastatin and amlodipine as an active ingredient, and relates to a pharmaceutical combination preparation having excellent dissolution rate and stability. will be.
  • Drugs used in the treatment of hypertension are divided into diuretics, sympathetic inhibitors, and vasodilators, depending on the mechanism of action, and the most widely used vasodilators are angiotensin 2 receptor blockers, ACE inhibitors, and calcium channel blockers.
  • Angiotensin 2 receptor blockers are primarily used in hypertensive patients who are unable to use ACE excipients and are also used to treat diabetic kidney disease and congestive heart failure. This substance blocks the binding of angiotensin 2 and angiotensin 2-AT1 receptors to inhibit the activation of angiotensin 2-AT1 receptors.
  • Representative drugs include telmisartan, balsatan, olmesartan, candesartan, and ibesatan. .
  • Amlodipine a representative dihydropyridine-based calcium channel blocker, relaxes smooth muscle in the arterial wall when the drug is absorbed, thereby lowering blood pressure and increasing blood flow to the myocardium.
  • Amlodipine is commercially available in the form of various salts such as besylic acid, maleic acid, and camsylic acid, and amlodipine besylate is the most widely used.
  • HMG-CoA reductase inhibitor is the most widely used in the treatment of hyperlipidemia and is involved in the conversion of HMG-CoA to Mevalonate, a rate determining step in the process of cholesterol biosynthesis in hepatocytes.
  • drugs that inhibit the synthesis of cholesterol in the liver by inhibiting enzymes include rosuvastatin, atorvastatin, and pitavastatin, and these compounds lower total cholesterol and LDL-cholesterol in the human body. And to elevate HDL-cholesterol levels in some individuals.
  • Hypertension and hyperlipidemia are representative cardiovascular diseases, and more than 50% of hypertension patients have hyperlipidemia and more than 50% of hyperlipidemia patients have high blood pressure. It is also clinically reported to be effective in the treatment of cardiovascular diseases, such as reducing the death and preventing diabetes. (American Journal of Cardiology, 93, 5, 603-606, 2004)
  • telmisartan is a poorly soluble drug having a very low solubility in the pH range of 3 to 9 or an alkalizing agent or a solubilizing agent because the drug should be rapidly released and absorbed in the stomach at a Tmax value of about 0.3 to 1.0 hours. It is customary to prepare formulations.
  • Amlodipine is an unstable free base that is greatly affected by light, heat, and water, and thus has a disadvantage in that its therapeutic effect is poor. Therefore, amlodipine is used in combination with various acid addition salts to maintain stability, but it is stable. Is still needed.
  • rosuvastatin is a drug belonging to the biopharmaceutical classification system II or III, and its bioavailability is very easily affected by the dissolution rate depending on the degree of ionization of the drug released at a specific pH.
  • the composition of the combination is difficult. When exposed to certain physicochemical conditions (acid, moisture, light), it is easy to decompose or oxidize, making it difficult to secure stability. It has been reported that the absorption rate of rosuvastatin decreases by about 50% when the pH of the body changes due to an alkalizing agent. (Curr Med Res Opin. 2008, 24, 4, 1231-1235)
  • Non-Patent Document 1 American Journal of Cardiology, 93, 5, 603-606, 2004
  • Non-Patent Document 2 Curr Med Res Opin. 2008, 24, 4, 1231-1235
  • the first mixing part and the second mixing part included in the co-formulation includes an excipient suitable for the properties of the drug, the first mixing It is to provide a pharmaceutical combination formulation in which the portion and the second mixing portion are present in physically separated form.
  • the present invention is a.
  • a first mixing portion comprising telmisartan, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof;
  • a second mixing portion comprising rosuvastatin, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof and amlodipine, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof Including,
  • the present invention is a.
  • a first mixing portion comprising telmisartan, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof, and a sugar or sugar alcohol;
  • a second mixing portion comprising rosuvastatin, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof and amlodipine, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof Including,
  • the present invention is a.
  • a first mixing portion comprising telmisartan, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof, and a sugar or sugar alcohol;
  • Rosuvastatin pharmaceutically acceptable salts thereof, optical isomers thereof, or hydrates or solvates thereof and amlodipine, pharmaceutically acceptable salts thereof, optical isomers thereof, or hydrates or solvates thereof, and microcrystalline cellulose A second mixing portion,
  • the present invention is a.
  • a first mixing portion comprising telmisartan, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof, and a sugar or sugar alcohol;
  • Rosuvastatin its pharmaceutically acceptable salts, its optical isomers, or its hydrates or solvates and amlodipine, its pharmaceutically acceptable salts, its optical isomers, or its hydrates or solvates, and croscarmellose sodium
  • a second mixing unit comprising a
  • the present invention is a.
  • a first mixing portion comprising telmisartan, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof, and a sugar or sugar alcohol;
  • Rosuvastatin its pharmaceutically acceptable salts, its optical isomers, or its hydrates or solvates and amlodipine, its pharmaceutically acceptable salts, its optical isomers, or its hydrates or solvates, and microcrystalline cellulose and croscarmell
  • a second mixing part comprising sodium rose
  • the first mixing portion and the second mixing portion are present in physically separated form, specifically, in two-layered form, and do not affect the dissolution rate of the three pharmacologically active ingredients included in the formulation of the present invention. It can be eluted quickly.
  • the preparation of the present invention by physically separating the first mixing unit and the second mixing unit due to the physical contact of telmisartan, an active ingredient of the first mixing unit and rosuvastatin and amlodipine, an active ingredient of the second mixing unit. Drug interactions can be inhibited.
  • an alkalizing agent is used to improve the absorption in vivo due to the characteristics of telmisartan having high solubility at high pH.
  • rosuvastatin which is rapidly disintegrated and absorbed in the gastrointestinal tract, Disintegration is delayed and dissolution rate is lowered by the alkalizing agent as described above.
  • the formulations of the present invention are not only good for in vivo absorption of telmisartan at low pH, but also can achieve excellent dissolution rate and stability of rosuvastatin and amlodipine. Since the first mixing portion and the second mixing portion are present in a physically separated form, specifically, in a two-layered crystal form, the disintegration rate may be controlled due to the physicochemical characteristics of the active ingredient and the excipient constituting each layer. The second mixing portion may disintegrate and elute before the first mixing portion.
  • the first mixing part may include sugar or sugar alcohol.
  • the sugar or sugar alcohol is not only the pharmacologically active ingredient of the first mixing part but also the two mixing parts.
  • the three pharmacologically active ingredients included in the formulation of the present invention may exhibit almost the same or similar dissolution pattern as the single agent containing the respective ingredient.
  • the second mixing part may include microcrystalline cellulose, croscarmellose sodium, or a mixture thereof.
  • the microcrystalline cellulose, croscarmellose sodium or a mixture thereof even if the second mixed portion comprising microcrystalline cellulose, croscarmellose sodium or a mixture thereof is present with the first mixing portion in the composite formulation of the present invention It does not affect the dissolution rate of the two pharmacologically active ingredients of the second mixing part as well as the pharmacologically active ingredients of the first mixing part, so that the three pharmacologically active ingredients included in the formulation of the present invention contain a single ingredient. Elution pattern can be almost the same or similar to the above.
  • the composite formulation of the present invention shows excellent stability due to little generation of flexible substances even under accelerated conditions.
  • a composite formulation comprising a first mixing portion containing a sugar or sugar alcohol and a second mixing portion containing microcrystalline cellulose, croscarmellose sodium or a mixture thereof is used as a pharmacological agent of the first mixing portion and the second mixing portion.
  • the active ingredient exhibits an excellent dissolution rate, can sufficiently exhibit its pharmacological activity, no problems such as deterioration of stability can occur at all, can significantly improve the convenience of medication, and mass production is easy.
  • the terms such as the first and the second are only used to distinguish the various layers, the films, the steps, and the like, respectively, but are not intended to indicate the order or the importance.
  • the terminology does not limit the features of layers, films, steps, and the like. Therefore, the terms such as the first and the second may not be used the same in the detailed description, the examples, the claims, and the like, and it is sufficient that the terms such as the first and the second can be distinguished from each other. .
  • ⁇ pharmaceutically acceptable '' is a pharmacologically acceptable autologous pharmaceutical agent having ordinary skill in the art, when administered to humans, typically without causing an allergic reaction such as gastrointestinal disorders, dizziness or the like. It may mean that the conventional use in the manufacture.
  • 'hydrate' is telmisartan, a pharmaceutically acceptable salt thereof, or an optical isomer thereof, rosuvastatin, a pharmaceutically acceptable salt thereof, or an optical isomer thereof, or amlodipine, a pharmaceutically acceptable salt thereof.
  • an optical isomer thereof, and the like are combined with water by a non-covalent intermolecular force, and may include a stoichiometric or non-stoichiometric amount of water.
  • the hydrate may include about 0.25 moles to about 10 moles of water based on 1 mole of the active ingredient, and more specifically about 0.5 moles, about 1 moles, about 1.5 moles, about 2 moles, about 2.5 moles, about 3 moles, about 5 moles, and the like.
  • a 'solvate' means telmisartan, a pharmaceutically acceptable salt thereof, or an optical isomer thereof, rosuvastatin, a pharmaceutically acceptable salt thereof, or an optical isomer thereof, or amlodipine, a pharmaceutically acceptable salt thereof.
  • a salt, or an optical isomer thereof, and a solvent other than water are bound by intermolecular force, and may include a solvent in stoichiometric or non-stoichiometric amounts.
  • the solvate may include a solvent molecule in a ratio of about 0.25 mol to about 10 mol based on 1 mol of the active ingredient, and more specifically about 0.5 mol, about 1 mol, about 1.5 mol, and about 2 mol , About 2.5 moles, about 3 moles, about 5 moles, and the like.
  • 'telmisartan' is 4 '-((1,4'-dimethyl-2'-propyl (2,6'-bi-1H-benzimidazol) -1'-yl) methyl)- It is a representative ARB (Angiotensin II Receptor Blockers) family of drugs having the chemical formula (1,1'-biphenyl) -2-carboxylic acid, which inhibits the final stage of the binding of the enzyme angiotensin 2 to AT1 receptor, which causes an increase in blood pressure. Lowering is a typical antihypertensive drug.
  • telmisartan as an active ingredient' may mean 'comprising telmisartan free base, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof.
  • 'layer comprising telmisartan as an active ingredient' refers to a layer comprising free base of telmisartan, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof.
  • 'Mixture comprising telmisartan as an active ingredient' refers to a mixture comprising a free base of telmisartan, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof.
  • 'Rosuvastatin' is [(E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R , 5S) -3,5-dihydroxyhept-6-enoic acid], which is a representative HMG-CoA reductase inhibitor or a lipid lowering agent called 'statin', which is used for hypercholesterolemia, hyperlipoproteinemia and atherosclerosis. Used for treatment.
  • 'including rosuvastatin as an active ingredient' may mean 'including rosuvastatin free base, pharmaceutically acceptable salt thereof, optical isomer thereof, or hydrate or solvate thereof.
  • 'layer comprising rosuvastatin as an active ingredient' refers to a layer comprising a free base of rosuvastatin, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof.
  • 'Mixture comprising rosuvastatin as an active ingredient' refers to a mixture comprising a free base of rosuvastatin, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof.
  • 'Amlodipine' is (RS) -3-ethyl-5-methyl-2-[(2-aminoethoxy) methyl] -4- (2-chlorophenyl) -6-methyl-1,4- It is a representative long-acting dihydropyridine-type calcium channel blocker with the formula of dihydropyridine-3,5-dicarboxylate, which expands peripheral arteries to reduce total peripheral blood vessel resistance, lowers heart rate, lowers blood pressure and reduces angina pain. It is a mechanism used to treat hypertension and angina.
  • 'including amlodipine as an active ingredient' may mean 'including amlodipine free base, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof.
  • 'layer comprising amlodipine as an active ingredient' refers to a layer comprising a free base of amlodipine, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof.
  • a mixture comprising as an active ingredient ' refer to a mixture comprising a free base of amlodipine, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof.
  • the first mixing portion including the sugar, sugar alcohol, or sugar and sugar alcohol, the dissolution rate of the two pharmacologically active ingredients of the second mixing portion as well as the pharmacologically active ingredient of the first mixing portion Effect can be achieved.
  • the sugar included in the first mixing portion may be any one or more selected from the group comprising lactose, sucrose, fructose, maltose and mixtures thereof.
  • the sugar alcohol contained in the first mixing part is mannitol, sorbitol, xylitol, maltitol, trytol, adonitol, isomalt, erythritol, arabitol, psylitol, dulcitol, inositol, trehalose, ribitol, It may be any one or more selected from the group comprising galactitol, lactitol and mixtures thereof.
  • the first mixing unit may include at least one of mannitol and sorbitol.
  • the sugar or sugar alcohol may be 30 to 80% by weight, specifically 45 to 75% by weight based on the total weight of the first mixing portion.
  • the formation of a wet channel in the preparation according to the present invention promotes the dissolution of the pharmacologically active ingredient gradually, thereby achieving the desired elution within a limited time. Aspects can be achieved.
  • the first mixing unit may further include an alkalizing agent.
  • the alkalizing agent is selected from the group consisting of sodium or potassium hydroxide as alkali metal hydroxide, arginine or lysine as basic amino acid, and meglumine (N-methyl-D-glucamine) It may be any one or more, specifically sodium hydroxide or meglumine.
  • the second mixing part may include microcrystalline cellulose and croscarmellose sodium to achieve excellent dissolution rate effects of two pharmacologically active ingredients of the second mixing part.
  • the microcrystalline cellulose may be 10 to 80% by weight, specifically 20 to 70% by weight based on the total weight of the second mixing portion.
  • the croscarmellose sodium may be 2 to 30% by weight, specifically 5 to 25% by weight, based on the total weight of the second mixing portion.
  • the sugar or sugar alcohol is 30 to 80% by weight based on the total weight of the first mixing portion
  • the microcrystalline cellulose is 10 to 80% by weight based on the total weight of the second mixing portion
  • the croscarmellose sodium may be 2 to 30% by weight based on the total weight of the second mixing part, and in this case, an excellent dissolution rate effect of the three pharmacologically active ingredients included in the formulation may be achieved.
  • the second mixing unit may further include a light shielding agent, and specifically, the light blocking agent may be any one or more selected from the group consisting of talc, titanium oxide, and a dye.
  • rosuvastatin included in the second mixing part may be decomposed or oxidized upon prolonged exposure to light to generate a lactone decomposition product, in which case the light blocking agent is added to the second mixing part. Including with rosuvastatin, it is possible to achieve the effect of suppressing the decomposition products by light even in the uncoated state.
  • the pharmaceutically acceptable salt of telmisartan included in the first mixing part may be selected from the group consisting of sodium salt, potassium salt, magnesium salt and calcium salt.
  • the daily dosage of telmisartan, its pharmaceutically acceptable salts, optical isomers thereof, or hydrates or solvates thereof may be from about 5 mg to about 240 mg, specifically And from about 10 mg to 180 mg, more specifically from about 20 mg to about 120 mg, and even more specifically from about 40 mg to about 80 mg.
  • the pharmaceutically acceptable salt of rosuvastatin included in the second mixing part may be an inorganic salt having a polyvalent cation, and specifically, may be a rosuvastatin calcium salt. It is not limited.
  • the daily dosage of rosuvastatin, a pharmaceutically acceptable salt thereof, optical isomer thereof, or a hydrate or solvate thereof may be about 0.3 mg to about 50 mg, specifically And from about 0.8 mg to 40 mg, more specifically from about 2.5 mg to about 30 mg, and even more specifically from about 5 mg to about 20 mg.
  • the amlodipine of the second mixing portion may include racemate of amlodipine, (S) -amlodipine or (R) -amlodipine, and specifically, racemate or (S) of amlodipine. ) -Amlodipine.
  • the pharmaceutically acceptable salt of amlodipine included in the second mixing part is in the group consisting of inorganic acid salts, organic acid salts, sulfonate salts, metal salts or alkaline earth metal salts, amino acid salts and amine salts. Can be selected.
  • pharmaceutically acceptable salts of amlodipine include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, Lactic acid, fumaric acid, maleic acid, salicylic acid, besylic acid, campylic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, lithium, sodium, potassium, calcium, magnesium, lysine, arginine, guanidine, dicysine It may be made of clohexylamine, N-methyl-D-glucamine, tris (hydroxymethyl) methylamine, diethanolamine, choline or triethylamine, and more specifically, it may be amlodipine
  • the daily dosage of amlodipine, its pharmaceutically acceptable salts, optical isomers thereof, or hydrates or solvates thereof may be about 1 mg to about 40 mg, specifically About 1.5 mg to 30 mg, more specifically about 2 mg to about 20 mg, and even more specifically about 2.5 mg to about 10 mg.
  • the formulation comprises from about 5 mg to about 240 mg of telmisartan, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof as telmisartan per unit dosage form. May include, specifically about 10 mg to about 180 mg, more specifically about 20 mg to about 120 mg, even more specifically about 40 mg to about And 80 mg.
  • the formulation comprises from about 0.3 mg to about 50 mg of rosuvastatin, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof as rosuvastatin per unit dosage form. May be included, specifically about 0.8 mg to about 40 mg, more specifically about 2.5 mg to about 30 mg, and more specifically about 5 mg to And about 20 mg.
  • the formulation may comprise from about 1 mg to about 40 mg of amlodipine, a pharmaceutically acceptable salt thereof, an optical isomer thereof, or a hydrate or solvate thereof as amlodipine per unit dosage form. It may include, specifically about 1.5 mg to about 30 mg, more specifically may include about 2 mg to about 20 mg, even more specifically about 2.5 mg to about 10 mg May be included.
  • the preparation may be administered once to several times a day, specifically, once a day to three times a day, more specifically once a day or twice a day, More specifically, it may be administered once a day, but is not limited thereto, and may be appropriately adjusted according to the condition of the patient.
  • the agent may treat or prevent cardiovascular disease
  • the cardiovascular disease may be hypertension, arterial spasm, deep vein, heart failure, cardiac hypertrophy, cerebral infarction, diabetes, obesity, hyperlipidemia, coronary artery disease , Chronic stable angina, vasospasmodic angina, stroke, myocardial infarction, transient ischemic attack, congestive heart failure, insulin resistance, impaired glucose tolerance, prediabetes, type 2 diabetes mellitus, diabetic nephropathy, dyslipidemia, cognitive decline, dementia Etc., specifically, hypertension, arterial spasm, deep vein, cardiac hypertrophy, cerebral infarction, hemostasis, coronary artery disease, chronic stable angina, vasoconstrictive angina, stroke, myocardial infarction, transient ischemic attack, congestive heart failure, and more. Specifically, it may be hypertension, hyperlipidemia and the like.
  • the formulation may be a tablet, specifically, may be a two-layer tablet.
  • the first mixing part may contain granules containing telmisartan as an active ingredient.
  • the granules may be dry granules or wet granules, specifically wet granules.
  • the second mixing part may contain granules containing rosuvastatin and amlodipine as active ingredients.
  • the granules may be dry granules or wet granules, but are not limited thereto.
  • the composite formulation may further include a film layer on the outer surface, specifically, the film layer may be a light-shielding film layer, moisture-proof film layer or sugar film layer and the like.
  • the film layer may be formed of a water-soluble material, specifically, as a water-soluble film layer forming material, hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl Cellulose (HEC), cellulose acetate phthalate (CAP), ethyl cellulose (EC), methyl cellulose (MC), polymethacrylate, polyvinyl alcohol-polyethylene glycol graft copolymer (Kollicoat (registered trademark); BASF) , Germany)), polyvinyl alcohol (PVA) (Opadry®; Colorcon, USA) and any one or more selected from the group consisting of a mixture thereof, but is not limited thereto.
  • HPMC hydroxypropylmethyl cellulose
  • HPC hydroxypropyl cellulose
  • HEC hydroxyethyl Cellulose
  • CAP cellulose acetate phthalate
  • EC ethyl cellulose
  • MC methyl cellulose
  • PVA polyvinyl alcohol
  • Rosuvastatin pharmaceutically acceptable salts thereof, optical isomers thereof, or hydrates or solvates thereof
  • Amlodipine pharmaceutically acceptable salts thereof, optical isomers thereof, or hydrates or solvates thereof
  • the agent may be present in a physically separated form of the layer containing telmisartan as an active ingredient, and the layer containing rosuvastatin and amlodipine as an active ingredient.
  • the first step may include the step of further mixing the alkalizing agent.
  • the first step may include preparing granules containing telmisartan as an active ingredient.
  • the step of preparing the granules may be by dry granulation method or wet granulation method, and more specifically by wet granulation method.
  • the second step may include preparing a granule comprising rosuvastatin and amlodipine as an active ingredient.
  • the step of preparing the granules may be by dry granulation method or wet granulation method, but is not limited thereto.
  • the present invention comprises a first mixing unit containing telmisartan as an active ingredient
  • compositions for treating or preventing a cardiovascular disease comprising a second mixture comprising rosuvastatin and amlodipine as an active ingredient.
  • the present invention comprises a first mixing unit containing telmisartan as an active ingredient
  • the present invention provides a method for preventing or treating cardiovascular disease by administering a pharmaceutical composition comprising a second mixture comprising rosuvastatin and amlodipine as an active ingredient in a therapeutically effective amount.
  • the present invention comprises a first mixing unit containing telmisartan as an active ingredient
  • composition comprising a second mixture comprising a rosuvastatin and amlodipine as an active ingredient.
  • the present invention is a pharmaceutical combination formulation containing all of telmisartan, rosuvastatin and amlodipine as an active ingredient, although all three components are contained in one pharmaceutical combination formulation without the interference phenomenon It is stable and can be used as a safe and effective therapeutic agent for hypertension and hyperlipidemia.
  • 1 is a graph showing that the telmisartan dissolution rate of the formulation of the example was excellent when comparing the formulation according to the example and the formulation according to the comparative examples.
  • Figure 2 is a graph showing the excellent rosuvastatin dissolution rate of the formulation of the Example when comparing the formulation according to the Example and the formulation according to the comparative examples.
  • 3 is a graph showing that the amlodipine dissolution rate of the formulation of the example was excellent when comparing the formulation according to the example and the formulation according to the comparative examples.
  • telmisartan dissolution rate of the formulation of the example was excellent when comparing the formulation according to the example and the formulation according to the comparative examples.
  • Figure 5 is a graph showing that the rosuvastatin dissolution rate of the formulation of the Example is excellent when comparing the formulation according to the Example and the formulation according to the comparative examples.
  • FIG. 6 is a graph showing that the amlodipine dissolution rate of the formulation of the example was excellent when comparing the formulation according to the example and the formulation according to the comparative examples.
  • telmisartan bioavailability of the formulation of the example is excellent when comparing the formulation according to the example and the formulation according to the comparative example.
  • a first mixing part including telmisartan as an active ingredient was prepared by the following method.
  • telmisartan, meglumine and povidone were dissolved in purified water, and then sprayed on sorbitol to prepare granules. After granulating the granules in a 20 mesh sieve, magnesium stearate was added and finally mixed in a mixer to prepare a first mixing portion containing telmisartan.
  • Example 1 of Table 1 a second mixing part including rosuvastatin and amlodipine as an active ingredient was prepared by the following method.
  • rosuvastatin calcium, amlodipine besylate, calcium hydrogen phosphate hydrate, microcrystalline cellulose, pregelatinized starch and croscarmellose sodium were mixed and sieved to a 30 mesh sieve.
  • Magnesium stearate was added and final mixed in a mixer to prepare a second mixing portion (granule) containing rosuvastatin and amlodipine.
  • a double-layer tableting machine was used to prepare a composite double-layer tablet consisting of a first mixing portion containing telmisartan and a second mixing portion containing rosuvastatin and amlodipine.
  • a first mixing part including telmisartan and a second mixing part including rosuvastatin and amlodipine were prepared as in Example 1.
  • first mixing portion and the second mixing portion were further mixed in a mixer, and then a monolayer tablet was prepared using a tablet press.
  • a monolayer tablet was prepared by a tablet press using only the first mixing part including telmisartan prepared in Comparative Example 1 per unit formulation as shown in Table 1 below.
  • Single-layer tablets were prepared with a tablet press using only the second mixing part including rosuvastatin and amlodipine prepared in Comparative Example 1 per unit formulation as shown in Table 1 below.
  • telmisartan, rosuvastatin and amlodipine over time was performed using the tablets of Example 1 and Comparative Examples 1 to 3 prepared above under the following conditions.
  • the control group was a cresto of telmisartan and amlodipine, twin star and rosuvastatin.
  • Mobile phase B A mixture of water, acetonitrile and methanol in a 2: 5: 3
  • UV absorbance photometer (wavelength 238 nm)
  • the dissolution rate measurement results are shown in FIGS. 1 to 3. As shown in the figure, the dissolution of telmisartan, rosuvastatin and amlodipine was remarkably lowered in the monolayer tablet formulations of Comparative Examples 1 to 3. On the other hand, in the case of the bilayer tablet formulation of Example 1, the dissolution rate of each active ingredient was not lowered, and it was confirmed that the dissolution rate was equivalent to that of the control group.
  • the combination preparations containing telmisartan, rosuvastatin and amlodipine are separated into portions containing telmisartan and portions containing rosuvastatin and amlodipine, respectively, without affecting the dissolution rate between the drugs. It was found that excellent dissolution rate could be maintained.
  • a first mixing part containing telmisartan as an active ingredient and containing D-mannitol was prepared by the following method.
  • telmisartan, meglumine and povidone were dissolved in purified water, and then sprayed on D-mannitol to prepare granules. After granulating the granules in a 20 mesh sieve, magnesium stearate was added and finally mixed in a mixer to prepare a first mixing portion containing telmisartan.
  • Example 2 of Table 2 a second mixing part including rosuvastatin and amlodipine as an active ingredient was prepared by the following method.
  • rosuvastatin calcium, amlodipine besylate, calcium hydrogen phosphate hydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, titanium oxide and mixed gray powder were mixed and sieved into a 30 mesh sieve.
  • Magnesium stearate was added and final mixed in a mixer to prepare a second mixing portion comprising rosuvastatin and amlodipine.
  • a double-layer tableting machine was used to prepare a composite double-layer tablet consisting of a first mixing portion containing telmisartan and a second mixing portion containing rosuvastatin and amlodipine.
  • a composite bilayer tablet was prepared in the same manner as in Example 2, except that crospovidone was used instead of croscarmellose sodium in the preparation of the second mixing unit according to the ingredients and contents shown in Example 2 in Table 2 per unit dosage form. It was.
  • Example 2 of Table 2 per unit formulation a composite bilayer tablet was prepared in the same manner as in Example 2, except that D-mannitol was used instead of microcrystalline cellulose in the preparation of the second mixing portion.
  • Example 2 According to the ingredients and contents shown in Example 2 in Table 2 per unit formulation, a composite bilayer tablet was prepared in the same manner as in Example 2, except that microcrystalline cellulose was used instead of D-mannitol in the preparation of the first mixing portion.
  • telmisartan, rosuvastatin and amlodipine over time was performed under the same conditions as in Experiment 1 using the tablets of Example 2 and Comparative Examples 4 to 7 prepared above.
  • the control group was a cresto of telmisartan and amlodipine, twin star and rosuvastatin.
  • the dissolution rate measurement results are shown in FIGS. 4 to 6.
  • the first mixing portion containing telmisartan includes D-mannitol and the second mixing portion containing rosuvastatin and amlodipine layers includes microcrystalline cellulose and croscarmellose sodium.
  • the purification of Example 2 did not lower the dissolution rate of all the active ingredients, it showed an excellent dissolution rate.
  • the tablets of Comparative Examples 4 to 7 as a result of using excipients different from those of Example 2 in the preparation of the first mixing section or the second mixing section, disintegration of each mixing section is delayed and the dissolution rate of the active ingredients is reduced. It was confirmed.
  • the composite preparation including two or more active ingredients, it was found that the use of excipients according to the dissolution and biological absorption characteristics of each active ingredient.
  • Examples 2 and Comparative Examples 1 to 3 were stored under accelerated conditions (40 ° C., 75% RH) after Alu-Alu packaging, and the amount of lead increased compared to the initial value after 3 and 6 months after the start of the test. .
  • Comparative Examples 2 and 3 are flexible even after 6 months storage under accelerated conditions using telmisartan (Comparative Example 2) or rosuvastatin and amlodipine (Comparative Example 3) as active ingredients. It was confirmed that the material is rarely generated and excellent in stability.
  • the tablets of Example 2 and Comparative Example 1 is a composite formulation containing three active ingredients, in the case of Comparative Example 1 prepared by mixing all of the active ingredients in a single-layer tablet storage for 6 months under accelerated conditions compared to the initial
  • the flexible material increased after the remarkable increase of the flexible material. It was confirmed that the stability was excellent because almost no flexible material occurred even after months of storage.
  • the preparation according to the present invention is between drugs By minimizing contact with substances that affect the stability and stability, it can be seen that improved stability can be achieved in the preparation and storage of the telmisartan, rosuvastatin and amlodipine combinations.
  • twinstar tablets 40/5 mg and Cresto tablet 20 mg were used as a control and compared with the tablets of Example 2 and Comparative Example 7.
  • the bioavailability evaluation result was obtained by pharmacokinetic parameters were calculated by analyzing the sample taken according to a predetermined time after the administration of the tablet, the comparison between the control group and the test group was 90% confidence in the average ratio of these after logarithmic conversion of the evaluation item value
  • the interval was calculated and evaluated.
  • Table 4 shows the lower limit and the upper limit of the test group individual values for the control mean.
  • the T / R ratio was calculated by dividing the geometric mean of the endpoint for the test group by the geometric mean of the endpoint for the control group.
  • Example 2 in which the dissolution rate was equal to that of the control group, the bioavailability confirmed by the T / R ratio value was also confirmed to be equivalent to that of the control group.
  • Comparative Example 7 which showed a lower dissolution rate compared to the control group, both AUC and Cmax value was low, so that the absorption in vivo was not properly achieved, it was confirmed that the overall bioavailability is low.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation comprenant du telmisartan, de l'amlodipine et de la rosuvastatine en tant que principes actifs. La présente invention concerne la formulation dans laquelle chacun des principes actifs a une excellent vitesse de dissolution, une stabilité élevée et une excellente biodisponibilité.
PCT/KR2019/005029 2018-04-25 2019-04-25 Préparation pharmaceutique WO2019209058A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180048144A KR102108396B1 (ko) 2018-04-25 2018-04-25 약학적 제제
KR10-2018-0048144 2018-04-25

Publications (1)

Publication Number Publication Date
WO2019209058A1 true WO2019209058A1 (fr) 2019-10-31

Family

ID=68295581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/005029 WO2019209058A1 (fr) 2018-04-25 2019-04-25 Préparation pharmaceutique

Country Status (2)

Country Link
KR (1) KR102108396B1 (fr)
WO (1) WO2019209058A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060110450A1 (en) * 2004-11-05 2006-05-25 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and amlodipine
CN101618215A (zh) * 2009-08-16 2010-01-06 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
CN103463082A (zh) * 2013-09-10 2013-12-25 扬子江药业集团四川海蓉药业有限公司 一种替米沙坦氨氯地平双层片及其制备方法
KR20150067777A (ko) * 2013-11-29 2015-06-19 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR20170007695A (ko) * 2015-07-08 2017-01-19 씨제이헬스케어 주식회사 암로디핀, 발사르탄 및 로수바스타틴을 포함하는 약학적 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060110450A1 (en) * 2004-11-05 2006-05-25 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and amlodipine
CN101618215A (zh) * 2009-08-16 2010-01-06 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
CN103463082A (zh) * 2013-09-10 2013-12-25 扬子江药业集团四川海蓉药业有限公司 一种替米沙坦氨氯地平双层片及其制备方法
KR20150067777A (ko) * 2013-11-29 2015-06-19 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR20170007695A (ko) * 2015-07-08 2017-01-19 씨제이헬스케어 주식회사 암로디핀, 발사르탄 및 로수바스타틴을 포함하는 약학적 조성물

Also Published As

Publication number Publication date
KR20190124071A (ko) 2019-11-04
KR102108396B1 (ko) 2020-05-07

Similar Documents

Publication Publication Date Title
WO2015102400A1 (fr) Préparation composite pour une administration orale comportant de l'ézétimibe et de la rosuvastatine
NO178135B (no) Fremgangsmåte for fremstilling av et peroralt preparat
WO2017007287A1 (fr) Composition pharmaceutique contenant l'amlodipine, le valsartan et la rosuvastatine
WO2018070671A1 (fr) Composition de comprimé oral de lénalidomide
WO2016159535A1 (fr) Formulation complexe pharmaceutique comportant de l'amlodipine, du losartan et de la chlorthalidone
WO2020009352A1 (fr) Préparation pharmaceutique contenant de la dapagliflozine/l-proline amorphe et son procédé de préparation
WO2017146286A1 (fr) Composition pharmaceutique à base d'extrait de feuille de ginkgo biloba utilisant une matrice de polymère hydrophile pour libération prolongée, et préparation à libération prolongée utilisant cette dernière
WO2015102282A1 (fr) Formulation complexe pharmaceutique comprenant un inhibiteur de récepteur d'angiotensine ii et un inhibiteur de réductase hmg-coa
WO2013157840A1 (fr) Composition composite présentant une stabilité améliorée et contenant de l'amlodipine et du rozaltan
WO2019209058A1 (fr) Préparation pharmaceutique
WO2021125824A1 (fr) Formulation pharmaceutique comprenant de la cibenzoline ou un sel de celle-ci
WO2015012633A1 (fr) Formulation complexe contenant de la metformine à libération prolongée et un inhibiteur de la hmg-coa réductase à libération immédiate
WO2020106020A1 (fr) Comprimé bicouche et son procédé de préparation
WO2019221488A1 (fr) Formulation pharmaceutique comprenant de l'apixaban et son procédé de préparation
WO2012077968A2 (fr) Formulation complexe contenant de l'hydrochlorure de lercanidipine et du valsartan et son procédé de préparation
WO2018199636A1 (fr) Formulation combinée comprenant un inhibiteur de la hmg-coa réductase et un bloqueur des canaux calciques
WO2017155350A1 (fr) Composition pharmaceutique pour administration par voie orale comprenant du (±)-2-[2- (3-carboxypropionyloxy)-3-diméthylaminopropoxy]-3'-méthoxybibenzyle ou des sels de celui-ci
WO2013187700A1 (fr) Formulation pharmaceutique combinée comprenant de la métformine et un inhibiteur de la hmg-coa réductase
WO2019212214A1 (fr) Préparation pharmaceutique
WO2010008224A2 (fr) Comprimés d’amlodipine à dissolution rapide à stabilité améliorée et leur procédé de fabrication
WO2020141825A1 (fr) Comprimé et son procédé de préparation
WO2013169082A1 (fr) Préparation orale à libération contrôlée de bosentan
WO2018088830A1 (fr) Composition pharmaceutique sous forme de comprimé à matrice monolithique comprenant de la chlortalidone ou son sel et de l'amlodipine ou son sel et procédé de préparation associé
WO2019143213A1 (fr) Préparation pharmaceutique
WO2019245150A1 (fr) Composition pharmaceutique comprenant du cilostazol et un médicament à base de statine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19792411

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19792411

Country of ref document: EP

Kind code of ref document: A1